Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T62206 | ||||
| Target Name | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | ||||
| Synonyms | Subtilisin/kexin-like protease PC9; Proprotein convertase 9; PC9; Neural apoptosis-regulated convertase 1; NARC1; NARC-1 | ||||
| Target Type | Successful | ||||
| Gene Name | PCSK9 | ||||
| Biochemical Class | Peptidase | ||||
| UniProt ID | PCSK9_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Chronic obstructive pulmonary disease | ||||
| Example drug | Bococizumab | Phase 3 | [1], [2], [3] | ||
| Tissue | Lung tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.01 Z-score: -0.03 P-value: 7.63E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Chronic obstructive pulmonary disease | ||||
| Example drug | Bococizumab | Phase 3 | [1], [2], [3] | ||
| Tissue | Small airway epithelium | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.02 Z-score: 0.07 P-value: 5.44E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Familial hypercholesterolemia | ||||
| Example drug | PF-04950615 | Phase 3 | [4], [3] | ||
| Tissue | Whole blood | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.07 Z-score: -0.3 P-value: 4.82E-02 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Coronary artery disease | ||||
| Example drug | LY3015014 | Phase 2 | [5], [3] | ||
| Tissue | Peripheral blood | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.13 Z-score: -0.62 P-value: 9.13E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| References | |||||
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7730). | ||||
| REF 2 | ClinicalTrials.gov (NCT02458287) Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia. | ||||
| REF 3 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
| REF 4 | ClinicalTrials.gov (NCT01975376) The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects. U.S. National Institutes of Health. | ||||
| REF 5 | ClinicalTrials.gov (NCT01890967) A Study of LY3015014 in Participants With High Cholesterol. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.